Literature DB >> 1310920

Increased energy expenditure in cystic fibrosis is associated with specific mutations.

A O'Rawe1, I McIntosh, J A Dodge, D J Brock, A O Redmond, R Ward, A J Macpherson.   

Abstract

1. Measurements of resting metabolic rate were made by open-circuit indirect calorimetry in 78 unrelated cystic fibrosis patients and 30 healthy control subjects. The aims of this study were: (i) to determine the range of variability in resting metabolic rate in cystic fibrosis, (ii) to relate this to pulmonary function and body size, and (iii) to investigate the hypothesis that, in cystic fibrosis, genotype exerts a significant influence on energy requirements. 2. There was no significant difference in age or body weight between patients with cystic fibrosis and control subjects. Resting metabolic rates for control subjects fell within +/- 10% of predicted values. Fifty-nine per cent of patients with cystic fibrosis had elevated resting metabolic rates (i.e. greater than 111% of predicted). Genotype analysis divided the patients with cystic fibrosis into three groups: delta F508 homozygotes, delta F508 heterozygotes and others. Patients homozygous for the delta F508 allele had a significantly higher resting metabolic rate (121% of predicted, 95% confidence interval 116-126%), compared with other genotypes (P less than 0.005). 3. There were significant differences in pulmonary function between the groups (P less than 0.005). However, after adjustment of individual resting metabolic rates for differences in pulmonary function by using analysis of covariance, resting metabolic rates remained significantly higher for delta F508 homozygotes than for other genotypes (P less than 0.05). 4. We conclude that there is a significant contribution to resting metabolic rate in cystic fibrosis associated with specific mutations that is not explained by declining pulmonary function.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1992        PMID: 1310920     DOI: 10.1042/cs0820071

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  11 in total

Review 1.  Enzyme contents of pancreatic extract preparations. Are they optimal?

Authors:  S Maguire; M C Goodchild
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

2.  Absence of leptin signaling allows fat accretion in cystic fibrosis mice.

Authors:  Ilya R Bederman; Gavriella Pora; Maureen O'Reilly; James Poleman; Kimberly Spoonhower; Michelle Puchowicz; Aura Perez; Bernadette O Erokwu; Alex Rodriguez-Palacios; Chris A Flask; Mitchell L Drumm
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-08-17       Impact factor: 4.052

3.  Resting energy expenditure and substrate oxidation rates in cystic fibrosis.

Authors:  I M Bowler; J H Green; S P Wolfe; J M Littlewood
Journal:  Arch Dis Child       Date:  1993-06       Impact factor: 3.791

4.  Resting energy expenditure and oxygen cost of breathing in patients with cystic fibrosis.

Authors:  S C Bell; M J Saunders; J S Elborn; D J Shale
Journal:  Thorax       Date:  1996-02       Impact factor: 9.139

5.  Expression and localization of the cystic fibrosis transmembrane conductance regulator mRNA and its protein in rat brain.

Authors:  A E Mulberg; L P Resta; E B Wiedner; S M Altschuler; D M Jefferson; D L Broussard
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

6.  Increasing calorie consumption in children with cystic fibrosis: replication with 2-year follow-up.

Authors:  L J Stark; L G Knapp; A M Bowen; S W Powers; E Jelalian; S Evans; M A Passero; M M Mulvihill; M Hovell
Journal:  J Appl Behav Anal       Date:  1993

7.  Measurement of fat digestion in early life using a stable isotope breath test.

Authors:  P McClean; M Harding; W A Coward; M R Green; L T Weaver
Journal:  Arch Dis Child       Date:  1993-09       Impact factor: 3.791

8.  Serum fatty acid profiles in cystic fibrosis patients and their parents.

Authors:  A B Christophe; W J Warwick; R T Holman
Journal:  Lipids       Date:  1994-08       Impact factor: 1.880

Review 9.  Recombinant growth hormone therapy for cystic fibrosis in children and young adults.

Authors:  Vidhu Thaker; Alexandra L Haagensen; Ben Carter; Zbys Fedorowicz; Brian W Houston
Journal:  Cochrane Database Syst Rev       Date:  2013-06-05

10.  Dietary intake and nutritional status in a Scandinavian adult cystic fibrosis-population compared with recommendations.

Authors:  Inger E Moen; Kristina Nilsson; Anna Andersson; Morten W Fagerland; Gjermund Fluge; Annika Hollsing; Marita Gilljam; Lena Mared; Tacjana Pressler; Henriette Santi; Olav-Trond Storrøsten; Lena Hjelte
Journal:  Food Nutr Res       Date:  2011-11-17       Impact factor: 3.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.